KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Raw Materials (2023 - 2025)

Historic Raw Materials for Aurinia Pharmaceuticals (AUPH) over the last 3 years, with Q3 2025 value amounting to $771000.0.

  • Aurinia Pharmaceuticals' Raw Materials changed N/A to $771000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $771000.0, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is 252.0% down from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Raw Materials stood at $771000.0.
  • In the past 5 years, Aurinia Pharmaceuticals' Raw Materials registered a high of $1.7 million during Q4 2023, and its lowest value of $771000.0 during Q1 2025.
  • Its 3-year average for Raw Materials is $1.2 million, with a median of $771000.0 in 2025.
  • The largest annual percentage gain for Aurinia Pharmaceuticals' Raw Materials in the last 5 years was 252.0% (2024), contrasted with its biggest fall of 252.0% (2024).
  • Aurinia Pharmaceuticals' Raw Materials (Quarter) stood at $1.7 million in 2023, then dropped by 2.52% to $1.7 million in 2024, then plummeted by 54.7% to $771000.0 in 2025.
  • Its Raw Materials stands at $771000.0 for Q3 2025, versus $771000.0 for Q2 2025 and $771000.0 for Q1 2025.